title: The Myth of Rescue Reversal in "Can't Intubate, Can't Ventilate" Scenarios.
abstract: An unanticipated difficult airway during induction of anesthesia can be a vexing problem. In the setting of can't intubate, can't ventilate (CICV), rapid recovery of spontaneous ventilation is a reasonable goal. The urgency of restoring ventilation is a function of how quickly a patient's hemoglobin oxygen saturation decreases versus how much time is required for the effects of induction drugs to dissipate, namely the duration of unresponsiveness, ventilatory depression, and neuromuscular blockade. It has been suggested that prompt reversal of rocuronium-induced neuromuscular blockade with sugammadex will allow respiratory activity to recover before significant arterial desaturation. Using pharmacologic simulation, we compared the duration of unresponsiveness, ventilatory depression, and neuromuscular blockade in normal, obese, and morbidly obese body sizes in this life-threatening CICV scenario. We hypothesized that although neuromuscular function could be rapidly restored with sugammadex, significant arterial desaturation will occur before the recovery from unresponsiveness and/or central ventilatory depression in obese and morbidly obese body sizes.
  
  
  
  We used published models to simulate the duration of unresponsiveness and ventilatory depression using a common induction technique with predicted rates of oxygen desaturation in various size patients and explored to what degree rapid reversal of rocuronium-induced neuromuscular blockade with sugammadex might improve the return of spontaneous ventilation in CICV situations.
  
  
  
  Our simulations showed that the duration of neuromuscular blockade was longer with 1.0 mg/kg succinylcholine than with 1.2 mg/kg rocuronium followed 3 minutes later by 16 mg/kg sugammadex (10.0 vs 4.5 minutes). Once rocuronium neuromuscular blockade was completely reversed with sugammadex, the duration of hemoglobin oxygen saturation >90%, loss of responsiveness, and intolerable ventilatory depression (a respiratory rate of ≤4 breaths/min) were dependent on the body habitus and duration of oxygen administration. There is a high probability of intolerable ventilatory depression that extends well beyond the time when oxygen saturation decreases <90%, especially in obese and morbidly obese patients. If ventilatory rescue is inadequate, oxygen desaturation will persist in the latter groups, despite full reversal of neuromuscular blockade. Depending on body habitus, the duration of intolerable ventilatory depression after sugammadex reversal may be as long as 15 minutes in 5% of individuals.
  
  
  
  The clinical management of CICV should focus primarily on restoration of airway patency, oxygenation, and ventilation consistent with the American Society of Anesthesiologist's practice guidelines for management of the difficult airway. Pharmacologic intervention cannot be relied upon to rescue patients in a CICV crisis.
authors.affiliation: From the *Department of General Anesthesia, Anesthesiology Institute, Cleveland Clinic, Cleveland, Ohio; †Department of Anesthesiology, University of Utah, Salt Lake City, Utah; and ‡Martinos Center for Biomedical Imaging, Department of Radiology, Massachusetts General Hospital, Boston, Massachusetts.
authors.forename: Mohamed
authors.initials: M
authors.lastname: Naguib
authors.forename: Lara
authors.initials: L
authors.lastname: Brewer
authors.forename: Cristen
authors.initials: C
authors.lastname: LaPierre
authors.forename: Aaron F
authors.initials: AF
authors.lastname: Kopman
authors.forename: Ken B
authors.initials: KB
authors.lastname: Johnson
mesh_terms: D000328:Adult; D000732:Androstanols / Q000008:administration & dosage* / Q000009:adverse effects; D000762:Anesthesia Recovery Period; D000768:Anesthesia, General; D015415:Biomarkers / Q000097:blood; D015992:Body Mass Index; D003198:Computer Simulation; D006801:Humans; D007442:Intubation, Intratracheal / Q000009:adverse effects*; D008168:Lung / Q000294:innervation*; D008297:Male; D008962:Models, Theoretical; D019148:Neuromuscular Blockade / Q000379:methods*; D009469:Neuromuscular Junction / Q000187:drug effects*; D003473:Neuromuscular Nondepolarizing Agents / Q000008:administration & dosage* / Q000009:adverse effects; D009765:Obesity / Q000150:complications* / Q000175:diagnosis; D009767:Obesity, Morbid / Q000150:complications / Q000175:diagnosis; D010108:Oxyhemoglobins / Q000378:metabolism; D012123:Pulmonary Ventilation / Q000187:drug effects*; D020127:Recovery of Function; D012121:Respiration, Artificial; D012125:Respiratory Center / Q000187:drug effects; D012307:Risk Factors; D000077123:Rocuronium; D013390:Succinylcholine / Q000008:administration & dosage* / Q000009:adverse effects; D000077122:Sugammadex; D013997:Time Factors; D047408:gamma-Cyclodextrins / Q000008:administration & dosage* / Q000009:adverse effects
chemical_list: D000732:Androstanols; D015415:Biomarkers; D003473:Neuromuscular Nondepolarizing Agents; D010108:Oxyhemoglobins; D047408:gamma-Cyclodextrins; D000077122:Sugammadex; D013390:Succinylcholine; D000077123:Rocuronium